Matrixyl FAQ: common questions answered
A topical cosmetic peptide with limited human evidence for making fine lines less visible.
Also called: Palmitoyl pentapeptide-4, Pal-KTTKS, Palmitoyl-Lys-Thr-Thr-Lys-Ser, C16-KTTKS, Palmitoyl pentapeptide-3, former name.
Cosmetic peptides · Lipid-linked collagen-fragment signal peptide.
- Is Matrixyl FDA-approved? No FDA-approved therapeutic product located. Cosmetic appearance claims differ from collagen-production drug claims. DailyMed listing alone is not approval.
- How do people take it? On the skin, mostly at night; days per week unstated. Reported 6–8 weeks. Source: reported by users, not an established dose.
- What's the difference between Matrixyl and Argireline? Matrixyl: a topical cosmetic peptide with limited human evidence for making fine lines less visible. Argireline: a topical cosmetic peptide with small, mixed wrinkle studies and limited skin penetration. Why people pair them: users combine wrinkle-focused peptides in one cream. No trial isolates added benefit from this pairing.
- Can I take it with Acetylhexapeptide-8? Users combine wrinkle-focused peptides in one cream. No trial isolates added benefit from this pairing. Multiple ingredients make benefits and irritation hard to attribute. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? It is unclear (WADA 2026). Matrixyl and pal-KTTKS are not named. S0 covers unapproved pharmacological substances; no specific cosmetic ruling found.
- How long does a mixed vial last? No validated home-mixed shelf life. Keep containers clean; warm or damp storage can weaken preservation.
Related to Matrixyl
- Argireline: A topical cosmetic peptide with small, mixed wrinkle studies and limited skin penetration.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Peptide products, Therapeutic Goods Administration · TGA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Consumer products: cosmetics, Office for Product Safety and Standards · 2025
- Allergens in Cosmetics, U.S. Food and Drug Administration · FDA
- Microbiological Safety and Cosmetics, U.S. Food and Drug Administration · FDA
- Notification of Cosmetics, Health Canada
- Wrinkle Treatments and Other Anti-aging Products, U.S. Food and Drug Administration
- Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials., Nukaly HY et al. · Frontiers in medicine · 2026
- Use of a Serum With the Infinite Glow® Device Improves Signs of Facial Aging: A Split-Face Case Report Using VISIA Analysis., Rodríguez D et al. · Cureus · 2026
- New Targets on Anti-wrinkles with Palmitoyl Pentapeptide-4: The Next Frontier in Anti-Aging Skincare, Lien L and Chen W · SOFW Journal · 2025
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.